Editorial
The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy
Abstract
The introduction of immune checkpoint inhibitors (ICIs), antibodies that target co-inhibitory molecules to improve anti-tumor immune responses, has dramatically changed the therapeutic landscape of several malignancies, particularly that of lung cancer (1,2).
